A practical reference on mass spectrometry: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | No marketing authorization in major jurisdictions |
| Scheduling example | Prescription-only supply in some countries | Handled as an unlicensed medicine where restricted |
| Sports classification | Prohibited peptide | Appears on anti-doping prohibited lists |
| Reported presentation | Lyophilized vial | Nominal content varies between vendors |
| Detection approach | Liquid chromatography–tandem mass spectrometry | Used in anti-doping and forensic testing |
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
== Clinical significance == AST is similar to alanine transaminase (ALT) in that both enzymes are associated with liver parenchymal cells. The difference is that ALT is found predominantly in the liver, with clinically negligible quantities found in the kidneys, heart, and skeletal muscle, while AST is found in the liver, heart (cardiac muscle), skeletal muscle, kidneys, brain, and red blood cells. As a result, ALT is a more specific indicator of liver inflammation than AST, as AST may be elevated also in diseases affecting other organs, such as myocardial infarction, acute pancreatitis, acute hemolytic anemia, severe burns, acute renal disease, musculoskeletal diseases, and trauma. The elevated AST level in hemorrhagic fever caused by crimean-congo hemorrhagic fever virus is associated with high mortality rate. AST was defined as a biochemical marker for the diagnosis of acute myocardial infarction in 1954. However, the use of AST for such a diagnosis is now redundant and has been superseded by the cardiac troponins. Laboratory tests should always be interpreted using the reference range from the laboratory that performed the test. Example reference ranges are shown below:
=== Helmchen's postulates === Helmchen's postulates are the theoretical models used to predict the elution order and extent of separation of diastereomers (including those formed from CDAs) that are adsorbed onto a surface. Although Helmchen's postulates are specific for amides on silica gel using liquid chromatography, the postulates provide fundamental guidelines for other molecules. Helmchen's Postulates are:
The decision was then appealed by WADA to the Court of Arbitration for Sport (CAS), which returned a guilty verdict on 12 January 2016. The guilty verdict was unsuccessfully appealed in the Federal Supreme Court of Switzerland. The thirty-four players were suspended for two years, affecting seventeen still-active AFL players who missed the 2016 season as a result of the findings.
=== Regulatory review === In 2015, the Australian Government's Department of Health published the results of a review of alternative therapies that sought to determine if any were suitable for being covered by health insurance; herbalism was one of 17 topics evaluated for which no clear evidence of effectiveness was found. Establishing guidelines to assess the safety and efficacy of herbal products, the European Medicines Agency provided criteria in 2017 for evaluating and grading the quality of clinical research in preparing monographs about herbal products. In the United States, the National Center for Complementary and Integrative Health of the National Institutes of Health funds clinical trials on herbal compounds, provides fact sheets evaluating the safety, potential effectiveness and side effects of many plant sources, and maintains a registry of clinical research conducted on herbal products. According to Cancer Research UK as of 2015, "there is currently no strong evidence from studies in people that herbal remedies can treat, prevent or cure cancer".
== Further reading == Bates, H. E. (1946). The Tinkers of Elstow: the Story of the Royal Ordnance Factory run by J. Lyons and Company Limited for the Ministry of Supply for the World War of 1939–1945. Privately published, Bird, Peter J. (1994). LEO: the First Business Computer. Wokingham: Hasler Publishing Limited. ISBN 0-9521651-0-4. Bird, Peter (2000). The First Food Empire. A History of J. Lyons & Co. Phillmore. Chichester, West Sussex. ISBN 1-86077-132-7. Ferry, Georgina (2003). A Computer Called LEO. Lyons Teashops and the World's First Office Computer. Fourth Estate. London. ISBN 1-84115-185-8. (Published in United States 2004, Hammersmith: Harper Perennial. ISBN 1-84115-186-6.) Caminer, David, John Aris, Peter Hermon and Frank Land (eds). (1996, 1998). User-Driven Innovation (published in the United States as LEO: The incredible Story of the World's first Business Computer). McGraw Hill. ISBN 0-07-009501-9, Harding, Thomas (2019). Legacy : one family, a cup of tea and the company that took on the world. London: William Heinemann. ISBN 978-1785150890.
Sources: en.wikipedia.org
DMSO is a polar aprotic solvent and is less toxic than other members of this class, such as dimethylformamide, dimethylacetamide, N-methyl-2-pyrrolidone, and hexamethylphosphoramide (HMPA). DMSO is frequently used as a solvent for chemical reactions involving salts, most notably Finkelstein reactions and other nucleophilic substitutions. It is also extensively used as an extractant in biochemistry and cell biology. Because DMSO is only weakly acidic, it tolerates relatively strong bases and as such has been extensively used in the study of carbanions. A set of non-aqueous pKa values (C-H, O-H, S-H and N-H acidities) for thousands of organic compounds have been determined in DMSO solution. Because of its high boiling point, 189 °C (372 °F), DMSO evaporates slowly at normal atmospheric pressure. Samples dissolved in DMSO cannot as easily be recovered compared to other solvents, as it is very difficult to remove all traces of DMSO by conventional rotary evaporation. One technique to fully recover samples is removal of the organic solvent by evaporation followed by addition of water (to dissolve DMSO) and cryodesiccation to remove both DMSO and water. Reactions conducted in DMSO are often diluted with water to precipitate or phase-separate products. The relatively high freezing point of DMSO, 18.5 °C (65.3 °F), means that at, or just below, room temperature it is a solid.
Researchers with the biotechnology company Rejuvenate Bio managed to extend the lifespans of elderly mice by 109%, reverse age-related frailty in the mice, and achieve signs of age reversal in human skin cells with gene therapy, employing partial cellular reprogramming.
Combination of small size, ease of engineering, high affinity and specificity makes Affibody molecules suitable alternative as monoclonal antibodies for both molecular imaging and therapeutical applications, especially for the receptor-overexpressing tumors. These proteins are characterized by a high rate of extravasation and rapid clearance of non-bound tracer from the circulation, as well as other nonspecific compartments, when compared to antibodies and their fragments
=== Light properties === Switch on time: LEDs light up extremely quickly. A typical red indicator LED achieves full brightness in under a microsecond. LEDs used in communications devices can have even faster response times. Focus: The solid package of the LED can be designed to focus its light. Incandescent and fluorescent sources often require an external reflector to collect light and direct it in a usable manner. For larger LED packages total internal reflection (TIR) lenses are often used to the same effect. When large quantities of light are needed, many light sources such as LED chips are usually deployed, which are difficult to focus or collimate on the same target. Area light source: Single LEDs do not approximate a point source of light giving a spherical light distribution, but rather a lambertian distribution. So, LEDs are difficult to apply to uses needing a spherical light field. Different fields of light can be manipulated by the application of different optics or "lenses". LEDs cannot provide divergence below a few degrees.
Lately Chief Executive, Convention of Scottish Local Authorities. For services to Local Government. Joshua MacAlister. Chair, Independent Review of Children's Social Care and Founder, Frontline. For services to Vulnerable Children. Norman Alexander MacDonald. Lately Local Councillor, Comhairle nan Eilean Siar. For services to the communities of Uig, Isle of Lewis and the Western Isles. Charles Piers Mackesy. Artist, Illustrator and Author. For services to Art and Literature. Catherine Elizabeth Magee. Chief Executive Officer, Dyslexia Scotland. For services to People with Dyslexia. Moni Mannings. Founder, EPOC (Empowering People of Colour). For services to Cultural Philanthropy, to Business and to Charity. Dr. Kathryn Jean Marks. Deputy Director, Environment Agency. For services to Flood Risk Management and to Equality, Diversity and Inclusion. Steven David Marshall. Chief Executive Officer, The Royal Naval, Army and Air Force Institute. For services to the Armed Forces. Sophia Mary Mason. Trustee, Garfield Weston Foundation. For services to Arts Philanthropy. Ian Stuart Matthews. Portfolio Leader, Ministry of Defence. For services to Defence. Samantha Kate Mayhew. Assistant Principal, Special Educational Needs and Disabilities, Weston College. For services to Further Education. Catherine McBride. Member, Trade and Agriculture Commission. For services to Economic Commentary and Trade Policy. Jonathan Robert McGoh. Chair and Co-Founder, The Reach Foundation and Co-Founder and Trustee, Reach Academy Feltham, London Borough of Hounslow. For services to Education.
Sources: en.wikipedia.org
=== Centre of Molecular Structure === Focuses on the structural and biophysical analysis of biological molecules. It is part of the Czech Infrastructure for Integrative Structural Biology (CIISB). The facility uses techniques including X-ray crystallography and small-angle X-ray scattering (SAXS), and offers biophysical methods for characterizing biomolecules.
The announcement of a new purported clean source of energy came at a crucial time: adults still remembered the 1973 oil crisis and the problems caused by oil dependence, anthropogenic global warming was starting to become notorious, the anti-nuclear movement was labeling nuclear power plants as dangerous and getting them closed, people had in mind the consequences of strip mining, acid rain, the greenhouse effect and the Exxon Valdez oil spill, which happened the day after the announcement. In the press conference, Chase N. Peterson, Fleischmann and Pons, backed by the solidity of their scientific credentials, repeatedly assured the journalists that cold fusion would solve environmental problems, and would provide a limitless inexhaustible source of clean energy, using only seawater as fuel. They said the results had been confirmed dozens of times and they had no doubts about them. In the accompanying press release Fleischmann was quoted saying: "What we have done is to open the door of a new research area, our indications are that the discovery will be relatively easy to make into a usable technology for generating heat and power, but continued work is needed, first, to further understand the science and secondly, to determine its value to energy economics."
It was determined that long-term exposure to low levels of confirmed mycotoxins could pose chronic health risks. For all the above reasons, a trend away from feed ingredients and toward USDA-certified ingredients fit for human consumption has developed. In 1999, another fungal toxin triggered the recall of dry dog food made by Doane Pet Care at one of its plants, including Ol' Roy, Wal-Mart's brand, as well as 53 other brands. This time the toxin killed 25 dogs. A 2005 consumer alert was released for contaminated Diamond Pet Foods for dogs and cats. Over 100 canine deaths and at least one feline fatality have been linked to Diamond Pet Foods contaminated by potentially deadly aflatoxin, according to Cornell University veterinarians.
Another objection questions whether pleasure is the only thing of value for individuals, citing things like virtue, achievement, friendship, and the satisfaction of desires as distinct sources. An influential counterexample to hedonism, proposed by philosopher Robert Nozick (1938–2002), imagines an experience machine that simulates a life filled with pleasures, which would be ideal from the perspective of hedonism. Pointing out that life in this virtual simulation lacks authenticity, Nozick argues that mere pleasure, by itself, is not the only source of value.
T4 (levothyroxine) is almost always preferred over T3 (liothyronine) when treating hypothyroidism. Treatment with T3 alone is not recommended, as it causes increased and potentially unsafe blood levels of free T3 (FT3). Combination treatment of hypothyroidism with T4 and T3 is generally only considered when treatment with T4 alone does not sufficiently resolve symptoms. As there is no evidence showing that combination treatment with T4 and T3 benefits patients, this approach is controversial, but it is supported by current guidelines of the European Thyroid Association and the British Thyroid Association for patients who do not respond at all to treatment with T4 alone.
Sources: en.wikipedia.org
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.
The peptide is listed as prohibited in competitive sport, so laboratories develop detection methods and monitor for its presence. Its appearance in enforcement reports reflects that classification rather than any approved athletic use. Analytical work in this area focuses on identifying the molecule and its breakdown products in biological samples.
Chromatographic separation combined with mass spectrometry identifies the peptide and estimates its amount in a sample. Testing can confirm whether the expected molecule is present and at what concentration. It cannot establish how a product was manufactured or whether it meets any purity standard.
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.